89Zr-DFO-girentuximab

DIAGNOSTIC_TEST2 trials

Sponsors

Telix Pharmaceuticals (Innovations) Pty Limited, NYU Langone Health

Conditions

Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell Carcinoma

Phase 1

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

RecruitingNCT07179770

NYU Langone HealthMetastatic Clear Cell Renal Cell Carcinoma

Start: 2025-09-15End: 2028-10-01Target: 12Updated: 2026-07-30

Unknown Phase

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Telix Pharmaceuticals (Innovations) Pty LimitedClear Cell Renal Cell Carcinoma

Updated: 2026-05-29

Related Papers

89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma

Pharmaceutics2026-02-19